Biotechs are getting hit hard on the stock market today. The group has been the No. 1 group out of IBD’s 197 industries, but it’s on track for its worst weekly decline in about a year. Some top-rated biotech stocks taking a beating include Celgene (CELG), Biogen (BIIB) and Regeneron (REGN). Watch this video for IBD chart analysis of each stock. Follow Alissa Williams on Twitter: @IBD_AWilliams.
Biogen Idec wowed the medical community and investors with its much-anticipated Alzheimer’s disease drug results Friday, sending its stock to a new high before closing up 9.8% to 475.98. At a medical conference in France, Biogen (BIIB) reported the results of a phase 1b study in which 166 patients were divided into five groups, one a placebo group and the others taking different doses of Biogen’s drug candidate aducanumab, or
The Medical-Biomed/Biotech group for eight straight weeks has been ranked No. 1 out of the 197 industry groups that IBD tracks. That means the group is bolstered by some of the best-performing stocks in the market. In this video, we analyze the charts of the top-rated “ABC’s” of the group: Alexion Pharmaceuticals (ALXN), Biogen Idec (BIIB) and Celgene (CELG). Biogen soared Friday on promising data for treating Alzheimer’s disease. Follow Alissa